Detail akcie Celularity Rg-A online

Business Summary: Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Celularity Inc revenues decreased 38% to $22.4M. Net loss applicable to common stockholders increased 51% to $67.4M. Revenues reflect Degenerative Disease segment decrease of 51% to $15.7M. Higher net loss reflects Fair Value Adjustments on Other Assets increase from $1.2M to $5.3M (expense), Loss on debt extinguishment increase of 63% to $6.4M (expense).